Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN70,4670,58-1,68
Msft2,76
Nokia4,7724,861,91
IBM1,74
Mercedes-Benz Group AG65,8265,841,26
PFE-0,15
28.05.2022 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 27.05.2022 17:35:23
Astra Zeneca (AZN.L, London)
Závěr k 27.5.2022 Změna (%) Změna (GBP) Objem obchodů (GBP)
105,80 0,32 0,34 114 276 930
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 28.05.2022
Popis společnosti
Obecné informace
Název společnostiAstraZeneca plc
TickerAZN
Kmenové akcie:Ordinary Shares
RICAZN.L
ISINGB0009895292
Poslední známé roční výsledky31.12.2021
Poslední známé čtvrtletní výsledky31.03.2022
Počet zaměstnanců k 31.12.2021 83 100
Akcie v oběhu k 30.04.20221 549 464 013
MěnaUSD
Kontaktní informace
Ulice1 Francis Crick Avenue
MěstoCAMBRIDGE
PSČCB2 0AA
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon442 073 045 000
Fax442076048151

Business Summary: AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Financial Summary: BRIEF: For the three months ended 31 March 2022, AstraZeneca plc revenues increased 56% to $11.39B. Net income decreased 75% to $386M. Revenues reflect Farxiga segment increase of 60% to $1B, Calquenc segment increase of 98% to $414M, United States segment increase of 79% to $4.13B, EX-China segment increase of 91% to $1.74B. Net income was offset by acquisition-related costs and credits increase from $0K to $1.18B (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals (NEC)
RBSS2004Pharmaceuticals - Generic & Specialty
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Offices of Other Holding Companies
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Offices of Other Holding Companies
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 28.05.2022
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorPascal Soriot6201.10.201201.10.2012
Chief Financial Officer, Executive DirectorAradhana Sarin4601.08.202101.08.2021
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZenecaMarc Dunoyer-01.08.202101.01.2013
Chief Human Resource Officer, General CounselJeffrey Pott-01.01.2009
Executive Vice President - Sustainability, Chief Compliance OfficerKatarina Ageborg-01.07.201101.07.2011
Executive Vice President - Operations and Information TechnologyPam Cheng50
Executive Vice President - BioPharmaceuticals Business UnitRuud Dobber57
Executive Vice President - Oncology Business UnitDavid Fredrickson-
Executive Vice President - Research and Development BioPharmaceuticalsMenelas Pangalos-
Executive Vice President - Vaccines and Immune TherapiesIskra Reic-